| 3.6 0.51 (16.5%) | 03-10 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term | |
|||
| Targets | 6-month : | 4.25 |
1-year : | 4.96 |
| Resists | First : | 3.63 |
Second : | 4.25 |
| Pivot price | 2.86 |
|||
| Supports | First : | 2.59 |
Second : | 1.95 |
| MAs | MA(5) : | 3.16 |
MA(20) : | 2.68 |
| MA(100) : | 2.05 |
MA(250) : | 1.38 |
|
| MACD | MACD : | 0.2 |
Signal : | 0.2 |
| %K %D | K(14,3) : | 86.8 |
D(3) : | 82.7 |
| RSI | RSI(14): 69.2 |
|||
| 52-week | High : | 4.21 | Low : | 0.61 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.[ PRLD ] has closed above the upper band by 1.2%. If price is in a uptrend band; this upward trend in price might continue. However a short term pullback inside the band is likely.Bollinger Bands are 25% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 3.64 - 3.66 | 3.66 - 3.67 |
| Low: | 2.96 - 2.97 | 2.97 - 2.98 |
| Close: | 3.57 - 3.6 | 3.6 - 3.62 |
Prelude Therapeutics Incorporated, a clinical-stage precision oncology company, focuses on the discovery and development of novel precision cancer medicines to underserved patients. It is developing PRT543 that is in Phase 1 clinical trials in select solid tumors and myeloid malignancies; and PRT811, which is in Phase 1 clinical trials in solid tumors, including glioblastoma multiforme. The company is also developing PRT1419, a potent and selective inhibitor of the anti-apoptotic protein; PRT2527, a potent inhibitor of CDK9 that exhibits high kinome selectivity; PRT-SCA2, which is in preclinical stage for multiple genomically selected cancers; PRT3645, a brain penetrant molecule that potently and selectively targets CDK4/6; and PRT-K4 that is in preclinical stage for solid tumors. The company was incorporated in 2016 and is headquartered in Wilmington, Delaware.
Tue, 10 Mar 2026
Prelude Therapeutics (PRLD) Q4 Loss Per Share Narrows Challenging Longstanding Bearish Narratives - simplywall.st
Tue, 10 Mar 2026
PRLD: Pipeline refocused on JAK2 V617F and KAT6A, with strong funding and key Incyte partnership - TradingView
Tue, 10 Mar 2026
Prelude Therapeutics Inc (PRLD) Reports Wider Loss for FY25 vs. Estimates - AlphaStreet
Tue, 10 Mar 2026
Prelude Therapeutics Reports 2025 Results, Highlights JAK2 Program - TipRanks
Tue, 10 Mar 2026
Prelude Therapeutics 2025 10-K: Revenue $12.14M, EPS (1.29) - TradingView
Tue, 10 Mar 2026
Prelude Therapeutics (NASDAQ:PRLD) Posts Quarterly Earnings Results, Beats Estimates By $0.13 EPS - MarketBeat
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 44 (M) |
| Shares Float | 16 (M) |
| Held by Insiders | 9.9 (%) |
| Held by Institutions | 57 (%) |
| Shares Short | 2,380 (K) |
| Shares Short P.Month | 1,680 (K) |
| EPS | -1.48 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0.76 |
| Profit Margin | 0 % |
| Operating Margin | -314.2 % |
| Return on Assets (ttm) | -51.9 % |
| Return on Equity (ttm) | -104 % |
| Qtrly Rev. Growth | 116.6 % |
| Gross Profit (p.s.) | 0.23 |
| Sales Per Share | 0.23 |
| EBITDA (p.s.) | -2.73 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -100 (M) |
| Levered Free Cash Flow | -65 (M) |
| PE Ratio | -2.45 |
| PEG Ratio | 0 |
| Price to Book value | 4.67 |
| Price to Sales | 15 |
| Price to Cash Flow | -1.58 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|